Sunday, June 5, 2011
An exciting Day 2 at ASCO
It was a full day of lectures on Topics on Ovarian Cancer, Posters on Health services and Developmental Therapeutics, Novel approaches to Improve Treatment Outcomes in Ovarian Cancer and Ovarian Cancer Oral abstracts.
Big News! Two studies ICON7 and OCEANS for newly diagnosed women and recurrent women respectively and Bevacizumab ( Avastin) were presented.
In a nutshell :
ICON7 ( Carbo/placitaxel + bevacizumab) is showing continued improved progression free survival and improved overall survival. The study ends in 2013.
OCEANS ( Carbo /gemcitabene + bevacizumab ) Showed clinically meaningful benefit in recurrent ovarian cancer.
There was also a report on the effect of screening on ovarian cancer mortality based on the Prostate, Lung,Colorectal, Ovarian (PLOC)cancer randomized screening trial. Conclusion: Screening ( CA-125 + Transvaginal Ultrasound) does not reduce ovarian cancer mortality.
Every Day is a Blessing!